Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis

被引：0
作者：
Xiang-Hua Ye
Liang Song
Ling Peng
Zhibin Bu
Sen-Xiang Yan
Jie Feng
Xin-Li Zhu
Xin-Biao Liao
Xue-Lin Yu
Danfang Yan
机构：
[1] Zhejiang University School of Medicine,Department of Radiotherapy, First Affiliated Hospital
[2] Peace Hosptial of Changzi Medical College,Department of Gastroenterology
[3] Zhejiang Hospital,Department of Ultrasound
[4] Nanfang Hospital,Department of Interventional Radiology
[5] Southern Medical University,Foreign Language Institution
[6] Jiangxi Science and Technology Normal University,undefined
来源：
Molecular Genetics and Genomics | 2015年 / 290卷
关键词：
CYP2E1; Polymorphism; Lung cancer; Susceptibility; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The previous, published data on the association between CYP2E1 RsaI (rs2031920), DraI (rs6413432) polymorphisms and lung cancer risk remained controversial. Hence, we performed a meta-analysis to investigate the association between lung cancer and CYP2E1 RsaI (5,074 cases and 6,828 controls from 34 studies), and CYP2E1 DraI (2,093 cases and 2,508 controls from 16 studies) in different inheritance models. Overall, significantly decreased lung cancer risk was observed (dominant model: odds ratio (OR) 0.80, 95 % confidence interval (95 % CI) 0.71–0.90; heterozygote model: OR 0.80, 95 % CI 0.70–0.90; additive model: OR 0.82, 95 % CI 0.72–0.94) when all the eligible studies were pooled into the meta-analysis of CYP2E1 RsaI polymorphism. In further stratified and sensitivity analyses, significantly decreased lung cancer risk was found among Asians (dominant model: OR 0.81, 95 % CI 0.71–0.93; heterozygous model: OR 0.81, 95 % CI 0.69–0.95), population-based studies (dominant model: OR 0.69, 95 % CI 0.54–0.88; recessive model: OR 0.39, 95 % CI 0.16–0.91; additive model: OR 0.67, 95 % CI 0.53–0.84; homozygous model: OR 0.34, 95 % CI 0.14–0.80; heterozygous model: OR 0.70, 95 % CI 0.54–0.91), hospital-based studies (dominant model: OR 0.80, 95 % CI 0.69–0.93; additive model: OR 0.84, 95 % CI 0.70–1.00; heterozygous model: OR 0.80, 95 % CI 0.68–0.95), lung AC (heterozygous model: OR 0.84, 95 % CI 0.71–1.00), smokers (dominant model: OR 0.72, 95 % CI 0.55–0.94), and non-smokers (dominant model: OR 0.74, 95 % CI 0.61–0.91). There was no significant association between CYP2E1 DraI polymorphism and the risk of lung cancer when all the eligible studies were pooled into the meta-analysis. However, in further stratified and sensitivity analyses, significant association was observed among smokers (dominant model: OR 0.49, 95 % CI 0.35–0.69). In summary, this meta-analysis indicates that CYP2E1 RsaI polymorphism is associated with lung cancer risk among Asians, CYP2E1 RsaI polymorphism may be associated with lung adenocarcinoma risk, and CYP2E1 RsaI and DraI polymorphisms may be associated with decreased lung cancer risk in smokers.
引用
收藏
页码：545 / 558
页数：13
相关论文
共 462 条
[1]  
Agarwal DP(2001)Genetic polymorphisms of alcohol metabolizing enzymes Pathol Biol 49 703-709
[2]  
Agundez JA(2008)Polymorphisms of human Curr Drug Metab 9 520-531
[3]  
Beckett WS(1993)-acetyltransferases and cancer risk Clin Chest Med 14 1-15
[4]  
Begg CB(1994)Epidemiology and etiology of lung cancer Biometrics 50 1088-1101
[5]  
Mazumdar M(1996)Operating characteristics of a rank correlation test for publication bias Carcinogenesis 17 2029-2034
[6]  
Bellec G(2008)Cytochrome P450 metabolic dealkylation of nine Am J Epidemiol 167 759-774
[7]  
Dreano Y(2002)-nitrosodialkylamines by human liver microsomes J Guangdong Coll Pharm 18 220-224
[8]  
Lozach P(2009)Glutathione Am J Epidemiol 169 802-814
[9]  
Menez JF(1997)-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and eta-analysis Lancet 350 1182-188
[10]  
Berthou F(1986)A case–control study of the impact of CYP2E1 RsaI polymorphism on the risk of lung cancer Control Clin Trials 7 177-634
12345678910